Economy
Key Facts
Two global private-equity firms have joined forces to chase Amil, reviving foreign interest in one of Brazil’s largest but most troubled health insurers.
Bain Capital has teamed up with Advent on a fresh proposal for the insurer, according to the Broadcast column of the newspaper Estadao. Both firms circled Amil separately during its last sale, in 2023, and are now said to be working together.
The owner, Jose Seripieri Filho, is reported to be willing to sell a stake while keeping control. That stance, if it holds, points to a deal closer to a partnership than an outright takeover.
Private-equity firms typically prefer full control, which lets them reshape management, cut costs and reset strategy without needing the seller’s approval at every turn. A minority stake with the founder still in charge is less common, though it can work when the owner brings industry relationships or regulatory credibility that a foreign fund cannot easily replicate.
Why private equity wants Amil
Amil is a heavyweight — Brazil’s fourth-largest health operator, with roughly 5.4 million members, 31 hospitals and 28 clinics, and revenue near R$26 billion (US$5.0 billion).
It is also a fixer-upper, an insurer that has bled money for years on its individual-plans book, a segment whose pricing no longer covers rising medical costs — exactly the kind of turnaround that buyout funds are built to run.
Individual health plans in Brazil are policies sold directly to consumers, rather than through employers, and regulators tightly control how much insurers can raise premiums each year. When medical inflation runs faster than allowed price increases, insurers lose money on every claim, which is what happened to Amil and why UnitedHealth wanted out.
Bain knows the terrain, having backed NotreDame Intermedica, later merged into Hapvida, before cashing out; both Bain and Advent have long tracked Brazil’s consolidating private-health market.
Such deals usually come with an operator — in Brazil’s recent health-insurance turnarounds, funds have leaned on executives like Irlau Machado Filho, who ran the Bain-backed NotreDame Intermedica, to cut costs and reset pricing.
From UnitedHealth to a new auction
Amil has changed hands before — UnitedHealth bought about 90 percent of it for US$4.9 billion in 2012, then spent years trying to leave Brazil, where its individual plans kept losing money.
The asset has deep roots — Amil was built by the late Edson Bueno, whose family later founded the diagnostics group Dasa, before UnitedHealth absorbed it in what was then one of Brazil’s biggest foreign acquisitions.
In late 2023, Seripieri, the founder of Qualicorp and an ally of President Lula, took it off UnitedHealth’s hands for about R$11 billion (US$2.1 billion). Only R$2 billion (US$390 million) of that was equity, with the rest, roughly R$9 billion (US$1.7 billion), assumed liabilities, much of it tax and litigation.
Since then he has reshaped it, including a 2025 deal that folded Amil’s hospitals into a venture with the diagnostics group Dasa. A sale of a stake to Bain and Advent would be the next step in carving value from a business bought cheaply and as-is.
The wider sector explains the interest, with Brazil’s private-health market consolidating around a few large groups while medical-cost inflation punishes standalone individual plans — the very weakness dragging on Amil, which buyers now frame as fixable rather than failing.
Consolidation in this context means fewer, bigger players absorbing smaller insurers to spread fixed costs, negotiate harder with hospitals and laboratories, and gain pricing power with regulators. The question is whether scale alone can overcome the structural mismatch between capped premiums and rising claims, or whether deeper reform of Brazil’s individual-plan rules will be needed.
Nothing is settled: the terms have not been disclosed, the companies typically decline to comment on market talk, and any transaction would face scrutiny from Brazil’s health and antitrust regulators before it could close. A change of control in health insurance is especially sensitive in Brazil, where regulators guard continuity of care for millions of members.
The ANS, Brazil’s health-insurance regulator, reviews ownership changes to ensure new owners can meet capital requirements and maintain service levels, while CADE, the antitrust authority, checks whether a deal would reduce competition or harm consumers. Both agencies can block, delay or impose conditions on transactions, adding months to any closing timeline.
Frequently Asked Questions
What is Amil?
Amil is one of Brazil’s largest health insurers and hospital operators, ranking fourth by market share with around 5.4 million members, 31 hospitals and 28 clinics. It earns revenue near R$26 billion (US$5.0 billion) a year, but its individual-plans business has been heavily loss-making, which has shaped every attempt to sell or restructure it.
Who is trying to buy it?
According to Estadao’s Broadcast column, the private-equity firms Bain Capital and Advent have teamed up on a new proposal. Both pursued Amil separately during its 2023 sale, and the current owner, Jose Seripieri Filho, is reported to be open to selling a stake while keeping control.
How did the current owner acquire Amil?
Jose Seripieri Filho, founder of the health-plan administrator Qualicorp, bought Amil from UnitedHealth in late 2023 for about R$11 billion (US$2.1 billion). Only R$2 billion (US$390 million) was equity, with the rest assumed liabilities, in an as-is deal that let UnitedHealth exit Brazil after years of losses.
Connected Coverage
LatAm Markets: Live Signals → — real-time movers, turnover leaders and FX across Latin America.
Read More from The Rio Times